Day: March 12, 2026

Cartier Cuts 7.1 g/t Au over 8.0 m at Portal (Cadillac); New Shallow High-Grade Gold Zone Discovered

Written by Customer Service on March 12, 2026. Posted in Public Companies.

VAL-D’OR, Quebec, March 12, 2026 (GLOBE NEWSWIRE) — Cartier Resources Inc. (″ Cartier ″ or the ″ Company ″) (TSXV: ECR; FSE: 6CA) is pleased to announce the ninth batch of results from the 100,000-m drilling program (2 drill rigs), for the Portal Sector, specifically from the North Simon Zone (″ NSZ ″) on the 100%-owned Cadillac Project, located in Val-d’Or (Abitibi, Quebec). Strategic Highlights from Portal Sector Drill Hole Results (Figures 1 to 4)CA26-314 intersected 7.1 g/t Au over 8.0 m including 38.8 g/t Au over 1.0 m (NS Zone). CA26-325 graded 6.8 g/t Au over 2.2 m (NS Zone). CA26-308 reported 3.3 g/t Au over 4.2 m (5C5 Zone).Significance for InvestorsHoles CA26-314 and 325 confirm the newly recognized NSZ high-grade gold zone near surface. The mineralization extends over 200 m in strike length and remains open in all...

NevGold Mobilizes Drill To Test Historical Leach Pads To Advance The Near-Term Antimony Production Scenario at Limo Butte

Written by Customer Service on March 12, 2026. Posted in Public Companies.

Vancouver, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that the permits have been received and a drill rig is mobilizing to its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. The drilling will test the historical gold heap leach pads for antimony with the objective of advancing the leach pads to a near-term antimony production scenario. This is one of the only near-term, at-surface antimony production scenarios in the United States with a path to potential antimony metal production by 2027. NevGold CEO, Brandon Bonifacio, comments: “There are very few opportunities like the near-term antimony production potential from the historical gold leach pads at Limo Butte. There is a clear mandate in the United...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Written by Customer Service on March 12, 2026. Posted in Public Companies.

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. (“Celularity”)...

Seanergy Maritime Announces the Acquisition of Two Japanese Capesize Newbuildings and Sale of Older Vessel; Provides Corporate Updates

Written by Customer Service on March 12, 2026. Posted in Mergers And Acquisitions.

Expansion of Newbuilding Program to Five Capesize and Newcastlemax Vessels Further Advances Fleet Renewal Strategy GLYFADA, Greece, March 12, 2026 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today that it has agreed to acquire two scrubber-fitted 181,500 dwt Capesize vessels to be constructed at a first-class shipyard in Japan and has entered into an agreement for the sale of the 2010-built M/V Squireship. The transactions expand the Company’s newbuilding program to five vessels (four Capesizes and one Newcastlemax) totaling approximately $384.0 million and underscore its disciplined fleet renewal strategy, which focuses on reallocating capital from older vessels into modern, fuel-efficient tonnage with attractive delivery positions. Acquisition of Two Japanese Newbuilding...

United Maritime Reports Fourth Quarter and Full-Year 2025 Financial Results

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Delivers 13th Consecutive Quarterly Dividend; Expands Capesize Exposure and Reallocates Capital to Strengthen Earnings and Free Cash FlowHighlights (in million USD, except LPS) Q4 2025 Q4 2024 12M 2025 12M 2024Net Revenues $6.6 $10.8 $37.8 $45.4Net Loss ($3.8) ($1.8) ($6.2) ($3.4)Adjusted Net Loss1 ($1.5) ($0.7) ($4.1) ($1.2)EBITDA1 ($0.7) $4.0 $10.8 $18.1Adjusted EBITDA1 $1.5 $5.1 $12.9 $20.3 Loss per share Basic & Diluted ($0.42) ($0.21) ($0.70) ($0.39)Adjusted loss per share Basic1 & Diluted1 ($0.17) ($0.09) ($0.46) ($0.14) __________________1 Adjusted earnings / (loss) per share, Adjusted Net Income / (loss), EBITDA and Adjusted EBITDA are non-GAAP measures. Please see the reconciliation below of Adjusted earnings / (loss) per share, Adjusted...

reAlpha (NASDAQ: AIRE) Reports Fourth Quarter and Full Year 2025 Results; Record Full-Year Revenue of $4.5 Million, Up 376% Year Over Year

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Delivering Revenue Growth and Increased Transaction Volume While Strengthening the Balance Sheet and Advancing Platform Integration DUBLIN, Ohio, March 12, 2026 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results for the quarter and full year ended December 31, 2025. Full Year Financial Highlights (All figures are approximate and compared to FY 2024 unless otherwise stated)Revenue increased 376% to $4.5 million, compared to $0.9 million in FY 2024. The increase was driven primarily by increased revenue from mortgage brokerage transactions from reAlpha Mortgage, subscription fees from AiChat’s AI conversational technologies, and revenues generated from Prevu’s real estate services following its acquisition in November...

Aemetis Reports Fourth Quarter and Full Year 2025 Results as Dairy RNG Platform Scales

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Dairy RNG production increased 61% year over year in Q4 2025; ethanol plant efficiency upgrade expected to increase plant cash flow from operations by approximately $32 million annuallyAemetis Biogas segment net income increased to $12.2 million in Q4 2025 Aemetis Biogas segment increased annual revenues and production tax credits by 53% Dairy RNG production increased 61% year over year in Q4 2025 Aemetis Biogas achieved annual segment net income of $6.9 million Capital investments increased 28% over the prior year to $26.0 million, supporting dairy RNG expansion and ethanol plant energy efficiency upgrades Dairy digester projects generated cash proceeds of $18 million during 2025 from the sale of investment tax credits Ethanol and Biogas operations generated additional income of $10.4 million from production tax credits during the fourth...

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine...

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027 CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026 Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the full year ended December 31, 2025, and...

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

– Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma – – Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales – – Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. “We are...

Day: March 12, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals